Rigel
corporate overview

pipeline

investors & media

careers



investors & media


Investor Relations Home

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and two preclinical programs with partners AstraZeneca for R256 in asthma and Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology.

Webcast ImageWebcast
Q2 2015 Rigel Pharmaceuticals Inc. Earnings Conference Call (Live)
August 4, 2015 at 4:30 p.m. ET
Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.98
Change (%) Stock is Up 0.15 (5.30%)
Volume475,185
Data as of 07/31/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
Title
2015 Q1 10-Q - PDF 
2015 Q1 10-Q
2015 Proxy Statement - PDF 
2015 Proxy Statement
2014 Annual Report - PDF 
2014 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
DateTitle 
07/28/15Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2015 financial results after market close on Tuesday, August 4, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-293... 
Printer Friendly Version
06/30/15Rigel Welcomes Keith A. Katkin to Board of Directors
SOUTH SAN FRANCISCO, Calif., June 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Keith A. Katkin, president and chief executive officer of Avanir Pharmaceuticals, has been appointed to Rigel's board of directors.  Mr. Katkin brings to Rigel's board extensive biopharmaceutical experience in commercial development, business development and operational management.   "Keith's background in directing product launches and his successful leadership of Avani... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitleRemind MePrior to Event
August 4, 2015
4:30 p.m. ET
Q2 2015 Rigel Pharmaceuticals Inc. Earnings Conference Call
days
Enter your e-mail address 
Most Viewed Links
Title
Updated 08/03/15
1.Q2 2015 Rigel Pharmaceuticals Inc. Earnings Conference Call
2.SEC Filings
3.Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
4.Rigel Announces First Quarter 2015 Financial Results
5.Current Financial Reports
* Data collected 07/26/15 - 08/02/15
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2014 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search